Toutes les études
Inscription sur invitationPHASE2, PHASE3INTERVENTIONNEL

An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007

This study is an extension of previous research, focusing on the long-term safety, how well it's tolerated, and the effectiveness of a medicine called tividenofusp alfa. This medicine is for children with a rare condition called Hunter syndrome, also known as Mucopolysaccharidosis Type II (MPS II). It's given through an IV (into a vein) and aims to help the brain and spinal cord. If you've already been part of related studies (DNLI-E-0002 or DNLI-E-0007) and meet certain conditions, you might be able to join this study. Participants will receive the medicine for up to 5 years, and for some, the original treatment they received in a previous study will remain unknown to everyone involved, ensuring fair evaluation.

En un coup d'œil

Statut
Inscription sur invitation
Phase
PHASE2, PHASE3
Sponsor
Denali Thérapeutiques Inc.
Objectif d'inscription
99
Démarrer
20 Sep 2023
Achèvement estimé
01 Jun 2027

De quoi parle cette étude ?

This study is an important next step for children living with Hunter syndrome, also known as Mucopolysaccharidosis Type II (MPS II). MPS II is a rare genetic condition that can affect many parts of the body, including the brain and spinal cord. Currently, treatments are available, but doctors are always looking for ways to improve care and find new options.

This particular study is testing a new investigational medicine called tividenofusp alfa (also known as DNL310). It's given through a drip into a vein (IV) and is designed to reach the brain and spinal cord. The main goal is to see how safe this medicine is over a longer period and how well children tolerate it. Researchers also want to understand how effective it is in managing the symptoms of Hunter syndrome long-term.

Because this is an 'extension study,' it's specifically for children who have already taken part in similar research studies (DNLI-E-0002 or DNLI-E-0007). By continuing to monitor these participants, researchers can gather valuable information about the medicine's long-term effects, which is crucial for helping to develop new treatments.

Points clés

  • This study is for children with Hunter syndrome (MPS II).
  • It's testing a new medicine called tividenofusp alfa given by IV.
  • The main goal is to check its long-term safety and how well it works.
  • Only children who completed previous studies (DNLI-E-0002 or DNLI-E-0007) can join.
  • Participation could last up to 5 years, with regular clinic visits.
  • Vous pouvez arrêter de participer à tout moment.

Qui peut être éligible ?

This study is for children who have already taken part in one of two previous research studies for Hunter syndrome (MPS II): Study DNLI-E-0002 or Study DNLI-E-0007.

If you were in Study DNLI-E-0002, you would need to have completed at least 49 weeks of that study and not have stopped the treatment early. If you were in Study DNLI-E-0007, you would need to have finished the entire treatment period in that study.

You would not be able to join this study if you have any serious or uncontrolled medical issues, or other health problems that the study doctors believe would make it unsafe for you to participate or would make it difficult to properly understand the study results.

Cet étude pourrait-elle vous convenir ?

Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.

  1. Have you or your child been diagnosed with Hunter syndrome (MPS II)?
  2. Did you or your child participate in study DNLI-E-0002 and complete at least 49 weeks without stopping early?
  3. OR, did you or your child participate in study DNLI-E-0007 and complete the entire treatment period?
  4. Do you or your child have any uncontrolled medical conditions or other health issues that a doctor might consider too significant for study participation?
Répondez à chaque question pour voir votre résultat.

En quoi consiste la participation ?

If you join this study, you will receive the study medicine, tividenofusp alfa, for up to 5 years. The medicine is given through an IV (intravenously), meaning it will be delivered directly into your bloodstream, likely at a hospital or clinic. Throughout this period, you will have regular visits to the study site. During these visits, the study team will carefully check your health, how you are feeling, and any effects the medicine might be having. They will perform various assessments to monitor the safety of the treatment and see how well it's working. These assessments might include physical exams, blood tests, and other procedures relevant to Hunter syndrome. The exact schedule of visits and tests will be explained in detail by the study team.

Risques et avantages potentiels

Taking part in any study has potential benefits and risks. The main potential benefit of this study is continued access to the investigational medicine tividenofusp alfa, which aims to help with Hunter syndrome. It contributes to understanding long-term safety and effectiveness, possibly leading to a new approved treatment. Potential risks could include side effects from the medicine, discomfort from IV infusions, or the time commitment for study visits. It's important to remember that you can stop participating in the study at any time, for any reason, without it affecting your usual medical care.

Locations (30)

  • Hôpital pour enfants UCSF Benioff Oakland
    Code postal vérifié
    Oakland, États-Unis
  • Ann and Robert H Lurie Children's Hospital of Chicago
    Code postal vérifié
    Chicago, États-Unis
  • Hackensack University Medical Center
    Code postal vérifié
    Hackensack, United States
  • UNC Children's Research Institute
    Code postal vérifié
    Chapel Hill, États-Unis
  • Cincinnati Children's Hospital Medical Center
    Code postal vérifié
    Cincinnati, United States
  • Children's Hospital of Philadelphia
    Code postal vérifié
    Philadelphie, États-Unis
  • The University of Texas Medical School at Houston
    Code postal vérifié
    Houston, États-Unis
  • Huntsman Cancer Hospital
    Code postal vérifié
    Salt Lake City, États-Unis
  • Sanatorio Mater Dei
    Code postal vérifié
    Buenos Aires, Argentine
  • Universitair Ziekenhuis Antwerpen
    Code postal vérifié
    Edegem, Belgium
  • UZ Brussel
    Code postal vérifié
    Jette, Belgique
  • Hospital Clinicas Porto Alegre
    Code postal vérifié
    Porto Alegre, Brazil

Questions fréquentes

What is Hunter syndrome (MPS II)?

Hunter syndrome is a rare genetic condition where the body can't break down certain complex sugars, leading to their build-up and causing various health problems, including developmental challenges.

What is tividenofusp alfa?

Tividenofusp alfa is an investigational medicine being tested in this study. It's designed to help the body process the substances that build up in Hunter syndrome, especially in the brain and spinal cord.

Comment le médicament est-il administré ?

The medicine is given through a drip into a vein, which is called an intravenous (IV) infusion.

How long will I be in this study?

If you join, you could receive the study medicine and be monitored for up to 5 years.

Can I join if I haven't been in a previous study?

No, this study is an extension and is only for children who have already participated in specific earlier studies (DNLI-E-0002 or DNLI-E-0007).

Comment en savoir plus

Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.

Intéressé à participer ?

Inscrivez votre intérêt

Partagez vos coordonnées et l'équipe de recherche pour "An Extension Study of the Long-Term Safety, Tolerability, an… vous contactera si vous êtes éligible. Consultez toujours votre médecin avant d'accepter de participer.

Discussion

Discussion communautaire

Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.